

CALVENZA™ EIV/EHV

Features

Benefits

High antigen mass

Maximizes magnitude of immune response
Maximizes duration of immune response

Novel adjuvant formulation

Stimulates and amplifies appropriate immune response with intranasal or intramuscular routes of administration

Incorporates both relevant North American and Eurasian EIV A₂ strains

Comprehensive, globally-relevant protection against widest variety of EIV viruses

Killed viral antigens

Ensures safety. No reversion to virulence. No shedding of vaccine virus

Unique EHV antigen

Stimulates protective antibody against EHV-1 and EHV-4

Twelve month EIV challenge studies

Proven, long-term protection. Exceeds USDA requirements

Challenge studies conducted against EHV-1 and EHV-4

Proven, broad-based EHV protection

Patented, flexible nasal applicator

Easy administration

Three-dose initial vaccination regime

Conforms to current AAEP vaccination guidelines